Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Kadcyla

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ESMO: Enhertu Wields 2-Fisted Power In Early Breast Cancer
    ESMO: Enhertu Wields 2-Fisted Power In Early Breast Cancer

    18 Oct 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/az-daiichi-unleash-enhertu-two-fisted-power-aiming-reshape-early-breast-cancer-landscape

    FIERCE PHARMA
    18 Oct 2025
    Share Share
    Az, Daiichi's Enhertu Notches Another Win In Early Breast Cancer
    Az, Daiichi's Enhertu Notches Another Win In Early Breast Cancer

    29 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/az-daiichis-enhertu-flexes-early-breast-cancer-prowess-another-ph3-win-topping-roches

    FIERCE PHARMA
    29 Sep 2025
    Share Share
    EU Backs AstraZeneca-Daiichi’s Enhertu for Breast Cancer
    EU Backs AstraZeneca-Daiichi’s Enhertu for Breast Cancer

    01 Mar 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/eu-backs-astrazeneca-daiichis-enhertu-breast-cancer-treatment-post-endocrine-2025-02-28/#:~:text=Feb%2028%20(Reuters)%20%2D%20The,suitable%20for%20additional%20hormone%20treatments.

    REUTERS
    01 Mar 2025
    Share Share
    Genentech's Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.
    Genentech's Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.

    02 Feb 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427

    FDA
    02 Feb 2022
    Share Share
    PhaseBio Names Jonathan Birchall as Chief Commercial Officer
    PhaseBio Names Jonathan Birchall as Chief Commercial Officer

    18 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211118006306/en

    BUSINESSWIRE
    18 Nov 2021
    Share Share
    Seagen undaunted by AstraZeneca-Daiichi's Enhertu
    Seagen undaunted by AstraZeneca-Daiichi's Enhertu

    30 Oct 2021

    // K. Dunleavy FIERCEPHARMA

    https://endpts.com/an-allergan-psychiatric-drug-failed-late-stage-depression-studies-but-abbvie-is-going-for-approval-anyway/

    K. Dunleavy FIERCEPHARMA
    30 Oct 2021
    Share Share